New Indication for Avastin

12 Feb 2013 8:52 AM | Lori Aubrey (Administrator)
AvastinĀ®  (bevacizumab), is NOW APPROVED in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatinbased chemotherapy, for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a
first-line Avastin-containing regimen.

View the details on our FDA approvals page!

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software